Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 669-675

  Crosby, Catherine M ^a   Nehete, Pramod ^d   Sastry, K Jagannadha ^c,d   Barry, Michael A ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; ANTIBODY; CAPSID PROTEIN; GAMMA INTERFERON; IIIA CAPSID CEMENT PROTEIN; UNCLASSIFIED DRUG; DRUG CARRIER; LIVE VACCINE; RECOMBINANT VACCINE;

ADENOVIRIDAE; ADULT; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUCOSA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROGENY; RHESUS MONKEY; SEROPREVALENCE; SYRIAN HAMSTER; TRANSGENE; VIRION; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; BLOOD; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MESOCRICETUS; MONONUCLEAR CELL; MUCOSAL IMMUNITY; PHYSIOLOGY; SECRETION (PROCESS); SUBLINGUAL DRUG ADMINISTRATION; VAGINA;

ADENOVIRIDAE; CRICETINAE; MACACA MULATTA; MESOCRICETUS AURATUS; MIRIDAE;

ADENOVIRUSES, HUMAN; ADMINISTRATION, INTRANASAL; ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNITY, MUCOSAL; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MESOCRICETUS; MICE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VAGINA; VIRUS REPLICATION;

EID: 84919429847     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02184-14     Document Type: Article

References (21)

1. Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin J E, Molnar-Kimber K, Mason BB, Bhat BM, Mizutani S, Hung PP. 1989. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci USA 86:6763-6767. http://dx.doi.org/10.1073/pnas.86.17.6763.
2. Cheng SM, Lee SG, Ronchetti-Blume M, Virk KP, Mizutani S, Eichberg JW, Davis A, Hung PP, Hirsch VM, Chanock RM. 1992. Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J Virol 66:6721-6727.
3. Natuk RJ, Chanda PK, Lubeck MD, Davis AR, Wilhelm J, Hjorth R, Wade MS, Bhat BM, Mizutani S, Lee S. 1992. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc Natl Acad Sci USA 89:7777-7781. http://dx.doi.org/10.1073/pnas.89.16.7777.
4. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, Robert-Guroff M. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 71:8531-8541.
5. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, Alipanah S, Murthy SC, Chanda PK, Nigida SM, Jr, Markham PD, Zolla-Pazner S, Steimer K, Wade M, Reitz MS, Jr, Arthur LO, Mizutani S, Davis A, Hung PP, Gallo RC, Eichberg J, Robert-Guroff M. 1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3:651-658. http://dx.doi.org/10.1038/nm0697-651.
6. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson J M, Ertl HC. 2003. Induction of CD8(+) T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171:6774-6779. http://dx.doi.org/10.4049/jimmunol.171.12.6774.
7. Vinner L, Wee EG, Patel S, Corbet S, Gao GP, Nielsen C, Wilson JM, Ertl HC, Hanke T, Fomsgaard A. 2003. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol 84:203-213. http://dx.doi.org/10.1099/vir.0.18589-0.
8. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, Li Y, Giles-Davis W, Cun A, Zhou D, Xiang Z, Letvin NL, Ertl HC. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol 81:6594-6604. http://dx.doi.org/10.1128/JVI.02497-06.
9. Barouch DH, Pau MG, Custers J H, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur J C, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of preexisting anti-Ad5 immunity. J Immunol 172:6290-6297. http://dx.doi.org/10.4049/jimmunol.172.10.6290.
10. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH. 2005. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J Virol 79:9694-9701. http://dx.doi.org/10.1128/JVI.79.15.9694-9701.2005.
11. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH. 2005. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vectorbased vaccines in mice and rhesus monkeys. J Virol 79:14161-14168. http://dx.doi.org/10.1128/JVI.79.22.14161-14168.2005.
12. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers J H, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174:7179-7185. http://dx.doi.org/10.4049/jimmunol.174.11.7179.
13. Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J. 2006. Novel replicationincompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 87:2135-2143. http://dx.doi.org/10.1099/vir.0.81956-0.
14. Campos SK, Barry MA. 2007. Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 7:189-204. http://dx.doi.org/10.2174/156652307780859062.
15. Khare R, Chen CY, Weaver EA, Barry MA. 2011. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11:241-258. http://dx.doi.org/10.2174/156652311796150363.
16. Crosby CM, Barry MA. 2014. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology 462-463:158-165. http://dx.doi.org/10.1016/j.virol.2014.05.030.
17. Thomas MA, Spencer JF, Wold WS. 2007. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 130:169-183. http://dx.doi.org/10.1385/1-59745-166-5:169.
18. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
19. Nehete PN, Gambhira R, Nehete BP, Sastry KJ. 2003. Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine. J Med Primatol 32:67-73. http://dx.doi.org/10.1034/j.1600-0684.2003.00011.x.
20. Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M. 2005. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79:10200-10209. http://dx.doi.org/10.1128/JVI.79.16.10200-10209.2005.
21. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin J E, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. 2013. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 13:238-250. http://dx.doi.org/10.1016/S1473-3099(12)70345-6.